4basebio PLC Stock OTC Markets
Stocks
FBSB.F
GB00BMCLYF79
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 81.58M 109M 95.48M 88.7M 153M 10.51B 156M 1.06B 414M 5.13B 408M 399M 17.79B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 81.88M 109M 95.83M 89.02M 154M 10.55B 156M 1.06B 415M 5.15B 409M 400M 17.86B | EV / Sales 2026 * |
29.2x | EV / Sales 2027 * | 8.94x |
| Free-Float |
38.72% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Amy Walker
CEO | Chief Executive Officer | 33 | 2026-02-09 |
Daniel Jones
CTO | Chief Tech/Sci/R&D Officer | - | 2025-02-28 |
Scott Lorimer
COO | Chief Operating Officer | - | 2026-03-11 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 52 | 2024-11-12 | |
| Director/Board Member | 55 | 2024-11-12 | |
Heikki Lanckriet
BRD | Director/Board Member | 48 | 2020-12-21 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 109M | |
| +1.08% | -5.74% | -4.98% | +10.45% | 46.06B | |
| +3.13% | +5.34% | +402.93% | +605.08% | 38.91B | |
| +2.14% | +2.95% | +10.83% | +65.45% | 35.57B | |
| +4.43% | -1.51% | +6.73% | -9.17% | 33.13B | |
| +1.23% | -2.05% | +0.56% | +30.76% | 26.42B | |
| +0.29% | -2.75% | - | - | 16.61B | |
| +14.71% | +12.62% | +38.50% | +146.99% | 15.08B | |
| -6.32% | -4.86% | +4.36% | +8.22% | 14.08B | |
| +1.82% | +0.19% | +1.45% | -30.74% | 12.81B | |
| Average | +2.10% | -0.43% | +57.55% | +103.38% | 26.52B | |
| Weighted average by Cap. | +2.22% | -1.28% | +75.35% | +129.70% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.8M 3.73M 3.28M 3.04M 5.25M 361M 5.35M 36.4M 14.2M 176M 13.99M 13.69M 611M | 12M 15.97M 14.04M 13.05M 22.5M 1.55B 22.91M 156M 60.86M 754M 59.95M 58.65M 2.62B |
| Net income | -17.1M -22.76M -20.01M -18.59M -32.07M -2.2B -32.64M -222M -86.72M -1.07B -85.43M -83.58M -3.73B | - |
| Net Debt | 300K 399K 351K 326K 563K 38.66M 573K 3.9M 1.52M 18.86M 1.5M 1.47M 65.42M | 25.7M 34.2M 30.08M 27.94M 48.2M 3.31B 49.06M 334M 130M 1.62B 128M 126M 5.6B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
